Dynavax to Present at the Cowen 42nd Annual Health Care Conference

EMERYVILLE, Calif., Feb. 23, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Wednesday, February 23, 2022
Information
Tags: 
Adjuvant, 1018, COVID-19, Company, Shingles, Vaccine, LinkedIn, Hepatitis B virus, Infection, CpG, Plague, Nasdaq, Conference, Union, Macdonald, Research, DPT vaccine, Pharmaceutical industry
Geotags: 
CALIFORNIA, EUROPEAN UNION
Organisation: 
DYNAVAX TECHNOLOGIES, COWEN 42ND ANNUAL HEALTH CARE CONFERENCE
Stock Symbol: 
NASDAQ-SMALL:DVAX
Summary
Key Points: 
  • EMERYVILLE, Calif., Feb. 23, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.
  • Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza.


Dynavax to Present at the Cowen 42nd Annual Health Care Conference

EMERYVILLE, Calif., Feb. 23, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T.

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts: 
Nicole Arndt 
[email protected] 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-cowen-42nd-annual-health-care-conference-301489032.html

SOURCE Dynavax Technologies

Copyright: 
2022 PR Newswire. All Rights Reserved.